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Introduction
Multiple myeloma (MM) is a malignant plasma-cell 
proliferative disorder. It is the second most common 
hematologic malignancy in the United States (Jemal 
et al., 2004). The overall estimated annual incidence 
of MM is 86,000 cases (Alexanian and Dimopoulos, 
1994). In the United States, MM is estimated to account 
for about 11,000 deaths each year (Kyle and Rajkumar, 
2004). The etiology of MM is not well understood, but 
lifestyle, occupational and environmental risk factors have 
been linked to the disease, as have age and male gender 
(Alexanian and Dimopoulos, 1994). The average 5-year 
survival of MM is estimated to be 33% (Alexanian and 
Dimopoulos, 1994). 
1Research Centre of Cancer, Shafa Hospital, Ahvaz Jundishapur University of Medical Science, Ahvaz, 2Department of Epidemiology 
and Biostatistics, School of Public Health, Tehran University of Medical Sciences, 3Health Research Center, Baqiyatallah University 
of Medical Sciences, Tehran, 4Social Determinants of Health Research Center, Qazvin University of Medical Sciences, Qazvin, 
Iran, 5Division of Psychosocial Research & Epidemiology, The Netherlands Cancer Institute, Amsterdam, The Netherlands  *For 
correspondence: Pakpour_Amir@yahoo.com 
Abstract
 Background: Reliable and validated instruments are needed in order to study the quality of life in myeloma 
patients. This study aimed to translate and explore the psychometric properties of the European Organisation for 
Research and Treatment of Cancer (EORTC) myeloma module (QLQ-MY20) in Iranian patients. Materials and 
Methods: Two hundred and fifteen patients with multiple myeloma (MM) were recruited from Imam Khomeini 
Hospital, Tehran. A standard forward-backward translation procedure was implemented. Participating patients 
were asked to complete the EORTC QLQ-C30 and the QLQ-MY20 three times, at study entry, after two weeks, 
and again after three months. Data were tested for the range of measurement, internal consistency, test-retest 
reliability, known group comparison, responsiveness and factor structure. Results: Mean age of the patients was 
60.7 years. No floor and ceiling effects were seen for the QLQ-MY20. Cronbach’s α was greater than 0.80 for all 
three multi-item scales (ranging from 0.82 to 0.93). All four scales had test-retest reliability of 0.85 or greater. 
Results of the confirmatory factor analysis that the hypothesized 3-scale measurement model of the QLQ-MY20. 
Moreover, the Persian version for the QLQ-MY20 differentiated between subgroups of the patients in terms of 
beta-2 microglobulin, fracture and performance status. The responsiveness of the QLQ-MY20 to change over 
time was confirmed within 3 months. Conclusions: the results of our study indicate that our Iranian version of 
the QLQ-MY20 is a feasible, reliable and valid questionnaire for assessing the condition-specific quality of life 
of patients with MM.  
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Despite significant improvement in treatment and 
management of MM, it still remains incurable (Kyle and 
Rajkumar, 2004). Therefore, palliating symptoms and 
prolonging patient’s life are considered as the major aims 
of MM treatment (Kyle and Rajkumar, 2004). However, 
MM treatment is associated with a number of side effect 
and toxicities that can increase the symptom burden 
associated with MM (e.g., bone pain, nausea, vomiting, 
fractures, hypercalcaemia, and fatigue) (Johnsen et al., 
2009). These symptoms can, in turn, have a negative 
impact on the patient’s daily functioning and quality of 
life. 
Health-related quality of life (HRQOL) is a potentially 
important endpoint in studies in MM, providing relevant 
data that can help physicians and patients choose the 
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most appropriate treatment. Although HRQOL has been 
assessed in a number of clinical studies in MM, a recent 
review concluded that there is as yet no consensus on 
how it should be assessed (Kvam et al., 2009). The most 
commonly used HRQOL questionnaire in MM research is 
the EORTC QLQ-C30 (Aaronson et al., 1993). Although 
the QLQ-C30 provides valuable information on generic 
aspects of HRQOL, it does not cover a range of MM-
specific issues (Osborne et al., 2012). For this reason, the 
EORTC developed a supplemental, myeloma-specific 
module (the QLQ-MY24), which has validated in studies 
including patients from Europe and the United States 
(Kontodimopoulos et al., 2012). However, the QLQ-
MY24 has not been used or evaluated previously in the 
Iranian setting. The aim of the study was therefore to 
translate and evaluate psychometrically the Iranian version 
of the QLQ-MY24. 
Materials and Methods
Study sample
The study was conducted from July, 2013 to March, 
2014. The study sample consisted of 215 patients with 
multiple myeloma referred for treatment to the Imam 
Khomeini Hospital, a large university hospital in Tehran. 
Patients were eligible for the study if they were 18 years 
or older, had been diagnosed with multiple myeloma at 
least one month prior to study entry, were able to read and 
speak Persian/Farsi. Patients who had a life expectancy 
of less than 3 months or had serious cognitive problems 
(as assessed by the Mini-Mental State Examination) were 
excluded from the study. The study protocol was approved 
by the ethics committee of the Qazvin University of 
Medical Sciences. All patients provided written informed 
consent to participate in the study. 
Data collection and measures 
Participating patients were asked to complete the 
EORTC QLQ-C30 and the QLQ-MY20 three times, at 
study entry, at two weeks, and again at three months. 
The EORTC-C30
The EORTC-C30 (version 3.0) is a cancer-specific 
measure of quality of life in cancer patients. It consists 
of 30 items organized into nine multi-item scales and six 
single items. The EORTC-C30 has been translated into a 
large number of languages, including Persian. The Persian 
version of the EORTC-C30 has been found to be valid 
and reliable when used with Iranian patients with cancer 
(Montazeri et al., 1999). 
The EORTC QLQ-MY20
The EORTC QLQ-MY20 has been developed as a 
supplement to the QLQ-C30 specifically for use among 
patients with multiple myeloma. It consists of 20 questions 
grouped into three scales assessing future perspective 
(3 items), disease symptoms (6 items), side effects of 
treatment (10 items), and a single item on body image. 
Responses are scored on a four-point scale, ranging from 
“not at all” (1) to “very much” (4). Scores are linearly 
transformed to a 0-100 scale. (Cocks et al., 2007). Higher 
scores on the body image and future perspective scales 
represent better outcomes, and higher scores on the 
symptoms and side effect scales poorer outcomes.
Translation procedure 
Two translators bilingual in Persian and English and 
with a medical background translated independently the 
original English version of the QLQ-MY20 into Persian. 
Subsequently, the coordinator of the translation process 
compared these translated versions and reconciled 
disparities to create a single, merged forward translation. 
This forward Persian translation of the QLQ-MY20 
was translated back into English by two native English 
speakers with a high level of fluency in Persian. The 
coordinator compared the English back translations with 
the original questionnaire and resolved differences in a 
session with the translators. The provisional translation 
was then piloted on 14 multiple myeloma patients (average 
age 58.12 [SD=9.14], 8 female and 6 male). The average 
time to complete the QLQ-MY20 was less than 6 minutes 
and the questionnaire was well understood and acceptable 
to patients.
Statistical analysis 
We examined the QLQ-MY20 score distributions, 
including the percentage of scores at the extremes of the 
scale. Floor or ceiling effect were considered present if 
more than 15% of respondents reported the highest or 
lowest possible score (Terwee et al., 2007).
We used Cronbach’s coefficient alpha (α) to assess 
internal consistency reliability, and considered α’s equal 
to or greater than 0.7 to be acceptable. We evaluated test–
retest reliability by calculating the intraclass Correlation 
Coefficient (ICC) (Rosner, 1995). 
We performed a confirmatory factor analysis (CFA) 
to examine the hypothesized 3-scale measurement 
model of the QLQ-MY20; future perspective, disease 
symptoms and side effects of treatment. The model fit was 
evaluated using Chi-square (χ2), the adjusted goodness 
of fit index (AGFI), χ2/df ratio, the standardized root 
mean square residual (SRMR) , the Root Mean Square 
Error of Approximation (RMSEA), the Non-Normed Fit 
Index (NNFI), the Comparative Fit Index (CFI), and the 
parsimonious normed fit index (PNFI). The thresholds of 
goodness-of-fit indices were as follow; a non-significant 
chi square (p>0.05), χ2/df ratio of 3:1 or smaller, a RMSEA 
less than 0.08, a CFI 0.90 or greater, a NNFI 0.90 or 
greater, an AGFI 0.90 or greater and a SRMR of 0.08 or 
less generally were considered a good fit [17].
We performed known-group validity testing, using the 
Wilcoxon Mann-Whitney statistic, to determine how well 
the QLQ-MY20 is able to discriminate between subgroups 
of patients formed on the basis of performance status, 
fractures and b-2 microglobulin level. It was hypothesized 
that patients with lower performance status, any fracture 
and high b-2 microglobulin level (≥4 mg/l) would report 
poorer scores on the questionnaire (Wisloff and Hjorth, 
1997; Cocks et al., 2007). All p-values were adjusted 
for multiple comparisons according to the Benjamini–
Hochberg procedure (Benjamini et al., 2006).
Finally, we assessed the responsiveness of the QLQ-
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MY20 to change over time in patients who responded 
to the treatment (i.e. complete response [CR], partial 
response [PR] or near complete response [NCR]). Change 
in QLQ-MY20 scores at baseline and three months after 
treatment in patients who responded to the treatment was 
computed using Wilcoxon rank sum test. Standardized 
response mean (SRM), an effect size index, was calculated 
to estimate the magnitude of the change over time (Liang 
et al., 1990). 
Data analyses were conducted with the SPSS 18.0 
(SPSS, Chicago, IL, USA) and LISREL 8.80.
Results 
Demographic and clinical characteristics of the 
samples are summarized in Table 1. Mean age of the 
patients was 60.7 years (SD=14.1). Almost all patients 
(201, 93.5%) completed the questionnaire in less than 6 
minutes, with a mean of 5.12 (SD=2.24). Floor (<12%) 
and ceiling effects (<14%) were low for all scales, varying 
between 4% and 13% (Table 2). Cronbach’s α was greater 
than 0.80 for all three multi-item scales (ranging from 0.82 
to 0.93) (Table 2). All four scales (including the single item 
body image measure) had test-retest reliability of 0.85 or 
greater. The disease symptoms scale had the highest test-
retest reliability (ICC=0.95).
Results of the CFA also are presented in Figure 1. They 
indicate that the three-factor, 19-item model converged and 
had an acceptable but marginal fit (χ2=259.75, degree of 
freedom=149, p<0.0001, RMSEA=0.080, SRMR=0.074, 
AGFI=0.96, CFI=0.97, NNFI=0.97, and PNFI=0.82). 
All scale items loaded significantly on related constructs 
and the standardized factor loadings were all above the 
minimum recommended value of 0.4. The correlations 
between the latent factors were significant and ranged from 
0.42 to 0.65. Factor loadings ranged from 0.59 to 0.98.
As hypothesized, patients with equal or higher levels of 
beta 2-microglobulin reported lower levels of functioning 
and higher levels of symptoms (Table 3). The effect sizes 
for the QLQ-MY20 subscales were all in the medium to 
large range (range 0.32 to 1.73). Low performance status 
was related significantly to lower levels of functioning 
and higher levels of symptoms, with effect sizes ranging 
from 0.38 to 0.46. More than 65% of the patients 
reported having a fracture (n=142). Scores on both the 
disease symptom and treatment side effects scales of the 
QLQ-MY20 were significantly higher in patients with a 
fracture than those without any fracture at baseline (effect 
size ranged from 0.0.32 to 0.53). Conversely, patients 
without any fracture at baseline reported higher levels of 
functioning (Table 3).
The responsiveness of the QLQ-MY20 to change over 
time (i.e., pre- versus post-treatment) was assessed for 
those patients who achieved at least a PR (Table 4). There 
Table 1. Characteristics of the Subjects 
Age (years) 60.71 (14.12)
Mean (SD) 
Sex 
 Male 120 (55.8%)
 Female  95 (44.2%)
Educational status  
 Illiterate  60 (27.9%)
 Primary school 46 (21.4%)
 Middle school 43 (20.0%)
 Secondary school 45 (21.0%)
 College  21 (9.8%)
Marital status  
 Single 28 (13.0%)
 Married  160 (74.5%)
 Widowed/divorced  27 (12.5%)
Occupational status  
 Employee  76 (35.4%)
 Unemployed  139 (64.7%)
World Health Organisation performance status (PS) 
 0 22 (10.2%)
 1 102 (47.4%)
 2 65(30.2%)
 3 17 (7.9%)
 4 9 (4.2%)
Disease status 
 Newly diagnosed 179 (83.3%)
 Relapsed/refractory 36 (16.7%)
Fractures present 
 Yes 73 (34.0%)
 No 142 (66.0%)
β-2 Microglobulin (mg/L)  
 <4 81 (37.7%)
 7-Apr 47 (21.9%)
 ≥8 34 (15.8%)
 Missing  53 (24.6%)
Transplant received  
 Yes 52 (24.2%)
 No  163 (75.8%)
Receiving bisphosphonate  
 Yes 174 (80.9%)
 No 41 (19.1%)
Chemotherapy  
 Conventional  147 (68.4%)
 High dose  68 (31.6%)
Figure 1. Standardized Estimated Factor-item 
Loadings, Error Variances, and Covariance for the 
Final Model of the QLQ-MY20
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were a total of 105 patients (49%) at follow-up who had 
either a CR, PR or NCR to their treatment. The patients 
reported significantly more side effects of treatment (p 
= 0.01), and poorer body image (p < 0.000) over time. 
Conversely, disease symptoms (p <0.000) and future 
perspective (p = 0.002) improved significantly over time. 
The effect sizes were relatively modest (ranging from , 
0.19 for the treatment side effects scale to 0.39 for body 
image. 
Discussion
The objective of this study was to examine the 
psychometric properties of the Iranian version of the 
QLQ-MY20 among patients with MM. The results show 
that the Iranian version of the QLQ-MY20 is acceptable 
to patients (with a response rate of more than 95% and 
only very minor amounts of missing data (<2%) for 
individual items). No significant floor or ceiling effects 
were observed. 
All of the QLQ-MY20 scales exceeded the 
recommended minimum alpha coefficient standard of 
0.70 for group assessment. In fact, the alpha coefficients 
observed in the current study were somewhat higher than 
those reported in the original English and Greek versions 
(Cocks et al., 2007; Kontodimopoulos et al., 2012). 
The test-retest reliability for the Iranian version of 
the QLQ-MY20 was investigated in patients who were 
clinically stable over a two-week interval. The ICCs 
were high for all scales. To our knowledge, no previous 
studies have reported on the test-retest reliability of 
this questionnaire. Future studies should examine 
reproducibility of the QLQ-MY20 across English-
speaking and multi-national samples.
The results of CFA in this study yielded a three 
structure of the Iranian version of the QLQ-MY20. The 
CFA had a good internal consistency and the empirically 
derived factor structure is supported by Cocks et al [10]. 
Most of the items loaded as expected and the factor 
loadings met the minimum recommended standard of 
0.4 value recommended by Hair et al. (2010). To the best 
of our knowledge, this the first study to explore factor 
structure of the QLQ-MY20. We would recommend that 
future studies assess the factor structure of the QLQ-MY20 
across different cultures and languages.
Known group validity was used to assess the ability 
of the QLQ-MY20 to discriminate between subgroups 
of the patients in terms of beta-2 microglobulin, fracture 
Table 2. Summary statistics for the QLQ-MY20 at baseline (N=215)
 Number Mean SD Floor N  Ceiling  Cronbach’s Normality
 of forms   (%) (%) alpha 
Future perspective 209 40.68 29.06 24(11.2%) 16 (7.4%) 0.816 0.02
Body image 215 77.57 37.55 17 (7.9%) 29 (13.5%) - 0.004
Disease symptoms  214 36.46 20.64 11 (5.1%) 22 (10.2%) 0.853 0.01
Side effects of treatment 215 29.59 16.54 9 (4.2%) 18 (8.4%) 0.938 0.008
Table 3. Known-groups Validity the QLQ-MY20 Questionnaire
beta-2 microglobulin performance status fractures
<4 mg/l ≥4 mg/l Effect 
size
Low High Effect 
size 
Present Absent Effect 
size(N=81) (N=81) (N=124) (N=91) (N=73) (N=142)
Future perspective
62.22 
(24.69)
22.11 
(12.45) 2.05
34.89 
(20.83)
46.18 
(32.37) 0.43
31.41 
(21.52)
77.77 
(38.49) 1.37
Body image 88.37 (31.84)
68.14 
(22.80) 0.73
62.62 
(33.40)
78.84 
(37.32) 0.46
59.91 
(24.72)
79.44 
(37.46) 0.58
Disease symptoms 36.78 (21.48)
68.22 
(26.58) 1.3
44.80 
(27.86)
34.31 
(22.53) 0.41
43.66 
(26.74)
33.83 
(32.67) 0.32
Side effects of treatment 19.33 (9.81)
31.87 
(13.78) 1.05
33.02 
(13.31) 
28.41 
(10.64) 0.38
32.51 
(14.12)
26.06 
(11.02) 0.53
*WHO performance status: High: scores 0/1. Low: score 2, 3, 4 (baseline), † Statistically significant for WHOPS, ‡ Statistically significant for 
response to treatment
Table 4. Responsiveness of the MY20 for Patients who Responded to the Treatment (n=105)
 Baseline  Follow-up  SRM* 0-3 months P valuea
 Mean (SD)
Future perspective 39.64 (29.15) 44.84 (20.51) 0.3 0.002
Body image 71.84 (38.23) 63.78 (31.39) 0.39 0.0003
Disease symptoms  38.23 (20.28) 30.22 (19.41) 0.23 0.0001
Side effects of treatment 29.21 (13.86) 31.97 (18.45) 0.19 0.012
* SRM standardized response mean, aWilcoxon signed-rank test
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and performance status. The results indicated that patients 
with lower levels of -2 microglobulin (>4 mg/l) reported 
better quality of life than those with higher level (≥4mg/l). 
In accordance with the present results, previous studies 
have demonstrated that low level of beta 2-microglobulin 
in serum was associated with response to treatment and 
survival in patients with MM (Greipp et al., 1993; Attal 
et al., 1996). Bone health is significantly affected by 
cancer therapy. Over 80% patients with MM experience 
skeletal complications such as bone loss and pathologic 
fracture (Sonmez et al., 2008). Bone loss places cancer 
patients at risk of fracture and thus compromised quality 
of life (Guise, 2006). The present findings are consistent 
with other studies that have found that patients without 
fractures and with high performance status report better 
quality of life (Cocks et al., 2007). 
In conclusion, the results of our study indicate that the 
Iranian version of the QLQ-MY20 is a feasible, reliable 
and valid questionnaire for assessing the condition-
specific quality of life of patients with MM. The QLQ-
MY20, in combination with the QLQ-C30, provides 
a comprehensive picture of the impact of MM and its 
treatment on the HRQOL of patients. 
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